Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-058699
Filing Date
2025-04-25
Accepted
2025-04-25 16:05:15
Documents
18
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A iobt-20250424.htm   iXBRL DEF 14A 778374
2 GRAPHIC img135870972_0.jpg GRAPHIC 85197
3 GRAPHIC img135870972_1.jpg GRAPHIC 17280
4 GRAPHIC img135870972_2.jpg GRAPHIC 46564
5 GRAPHIC img135870972_3.jpg GRAPHIC 17280
6 GRAPHIC img135870972_4.jpg GRAPHIC 391357
7 GRAPHIC img135870972_5.jpg GRAPHIC 334338
  Complete submission text file 0000950170-25-058699.txt   2976691

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT iobt-20250424.xsd EX-101.SCH 7930
20 EXTRACTED XBRL INSTANCE DOCUMENT iobt-20250424_htm.xml XML 7472
Mailing Address OLE MAALOES VEH 3 COPENHAGEN G7 2200
Business Address OLE MAALOES VEH 3 COPENHAGEN G7 2200 4570702980
IO Biotech, Inc. (Filer) CIK: 0001865494 (see all company filings)

EIN.: 870909276 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41008 | Film No.: 25873793
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)